The invention concerns a liquid pharmaceutical formulation suitable for oral administration comprising a suspension of an effective amount of micronized 2-(2- nitro-4-trifluoromethylbenzoyl)-13-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable e.g. in hereditary tyrosinaemia type I.

The invention provides pharmaceutical formulations of nitisinone stabilized for long term storage. Exemplary formulations include one or more acid pH modulator

A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism including for example oculocutaneous albinism types OCA1a and OCA1b as well as ocular albinism type 1 resulting from mutations in the GPR143 gene as well as the OCA2 OCA3 or OCA4 genes by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (242-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-13-dione) also known as...

The invention concerns a liquid pharmaceutical formulation suitable for oral administration comprising a suspension of an effective amount of micronized 2-(2- nitro-4-trifluoromethylbenzoyl)-13-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable e.g. in hereditary tyrosinaemia type I.

The invention concerns a liquid pharmaceutical formulation suitable for oral administration comprising a suspension of an effective amount of micronized 2-(2- nitro-4-trifluoromethylbenzoyl)-13-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable e.g. in hereditary tyrosinaemia type I.

A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism including for example oculocutaneous albinism types OCA1a and OCA1b as well as ocular albinism type 1 resulting from mutations in the GPR143 gene as well as the OCA2 OCA3 or OCA4 genes by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (242-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-13-dione) also known as...

A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (242-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), als...

A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism including for example oculocutaneous albinism types OCA1a and OCA1b as well as ocular albinism type 1 resulting from mutations in the GPR143 gene as well as the OCA2 OCA3 or OCA4 genes by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-l3-dione) also known a...

A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism including for example oculocutaneous albinism types OCA1a and OCA1b as well as ocular albinism type 1 resulting from mutations in the GPR143 gene as well as the OCA2 OCA3 or OCA4 genes by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-l3-dione) also known a...